KOBE Biomedical Innovation Cluster newsletter vol. 60
- June 2025 -

vol. 60 June 2025
~ Celebrating 60th Edition since 2020.
Thank you for being with us! ~
Hello,
We are pleased to report that Kobe Biomedical Innovation Cluster participated in the BIO International Convention 2025 held from June 16 to June 19 in Boston, USA. The BIO International Convention is one of the world’s largest biotechnology industry events, bringing together cutting-edge research, innovative technologies, and global business collaboration opportunities.
At our booth, together with Osaka Prefecture, we promoted the Kansai life science ecosystem and KBIC’s member companies who are seeking strategic partners overseas. During the convention, many visitors stopped by, and we had the opportunity to receive valuable feedback and questions. The event also allowed us to engage in meaningful interactions with companies from both Japan and abroad.
We sincerely thank everyone who visited our booth and we look forward to staying in touch and continued engagement!
If you missed our past issues of KBIC newsletter, please visit Newsletter Archive.
FBRI Editorial Team
NEWS
VCCT Inc. and Eisai Co., Ltd. Enter Collaborative Research Agreement to Develop Retinal Organoid-Based Drug Toxicity Testing Platform
VCCT Inc. (Headquarters: Kobe, Japan; President: Masayo Takahashi), is pleased to announce that it has entered into a collaborative research agreement with Eisai Co., Ltd. (Headquarters: Tokyo, Japan) to develop a drug toxicity testing platform utilizing iPSC derived retinal organoids.
Eisai has established internationally recognized standards in toxicity assessment using pluripotent stem cells derived cardiomyocytes, demonstrating its leading expertise in the drug discovery field.
Visit KBIC Website!
We help international medical business thrive in Japan with world-class research institutes and facilities.

